Stocksigma LogoStocksigma Logo

Transgene Biotek Clarifies Non-Applicability of Regulation 32(1) for Q2 FY27

Transgene Biotek informed the BSE that Regulation 32(1) of SEBI LODR Regulations regarding the Statement of Deviation or Variation is not applicable for

Transgene Biotek Clarifies Non-Applicability of Regulation 32(1) for Q2 FY27

Transgene Biotek Ltd 路 Others (Uncategorized) 路 04 Oct 2026, 12:08 am

Transgene Biotek Clarifies Non-Applicability of Regulation 32(1) for Q2 FY27 Transgene Biotek informed the BSE that Regulation 32(1) of SEBI LODR Regulations regarding the Statement of Deviation or Variation is not applicable for the quarter ended 30th Sep'26. The company confirmed that no funds were raised through public, rights, preferential issues, or QIPs during the reporting period, rendering deviation disclosures inapplicable. Furthermore, the company noted its inability to submit via XBRL mode due to system restrictions on NIL entries.

Original exchange filing (PDF)

More announcements from Transgene Biotek Ltd

All Transgene Biotek Ltd announcements